FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

60 letters match. Newest first.

  1. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  2. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  3. ProRx LLC

    ProRx LLC, an outsourcing facility, made sterile compounded drugs under insanitary conditions and without required 503B eligibility.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk
  5. Thrive Health and Wellness, LLC dba Thrive Health Solutions

    FDA warned Thrive Health and Wellness, a Colorado repackager, that sterile drugs were made in unsanitary conditions and sold without approval.

    High risk
  6. Apollo Care, LLC

    FDA cited Apollo Care for insanitary conditions and quality failures in sterile compounded drugs, including a sterility-assurance recall.

    High risk
  7. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  8. GenoGenix LLC

    FDA warns GenoGenix over insanitary sterile compounding, endotoxin-contaminated NAD+, and unapproved drugs.

    High risk
  9. MedisourceRx

    MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.

    Medium
  10. Boothwyn Pharmacy, LLC

    Boothwyn Pharmacy made sterile drugs in insanitary conditions and shipped lots that failed sterility and potency tests.

    High risk
  11. Revive Rx LLC dba Revive Rx Pharmacy

    FDA warns Revive Rx Pharmacy over insanitary production of sterile compounded drugs, citing contamination risks.

    High risk
  12. PQ Pharmacy, LLC

    FDA warns PQ Pharmacy, a Florida sterile drug compounder, that its products were made under unsafe conditions.

    High risk
  13. Turbare Manufacturing

    FDA warns outsourcing facility Turbare Manufacturing of Conway, Arkansas, for making sterile drugs under insanitary conditions.

    High risk
  14. Wells Pharma of Houston, LLC

    FDA warns Wells Pharma of Houston over sterile compounded drugs made under insanitary conditions.

    High risk
  15. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  16. Staska Pharmaceuticals, Inc.

    FDA warns Staska Pharmaceuticals, a Nebraska outsourcing facility, that sterile compounded drugs had contamination risks and labeling problems.

    High risk
  17. OSRX, Inc.

    OSRX, a Montana compounding facility, made sterile ophthalmic drugs under insanitary conditions with quality and labeling failures.

    High risk
  18. Tailstorm Health Inc. dba Medivant Health

    Tailstorm Health (Medivant Health) sterile compounded drugs had insanitary conditions and current good manufacturing practice failures, prompting a bevacizumab recall.

    High risk
  19. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.

    High risk
  20. Empower Clinic Services, LLC dba Empower Pharma

    FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

    High risk
  21. Nubratori, Inc. dba Nubratori Rx

    FDA cited Nubratori Rx, a sterile compounding outsourcing facility, for insanitary conditions and manufacturing quality failures that may contaminate its drug products.

    High risk
  22. Annovex Pharma, Inc.

    FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.

    High risk
  23. Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals

    FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.

    High risk
  24. ProRx, LLC

    FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.

    High risk
  25. Fagron Compounding Services, LLC dba Fagron Sterile Service

    FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.

    High risk
  26. Stokes Healthcare Inc. dba Epicur Pharma

    Sterile compounding facility Epicur Pharma made drugs under insanitary conditions and with serious quality failures, FDA says.

    High risk
  27. Central Admixture Pharmacy Services, Inc.

    FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.

    High risk
  28. Northern VA Compounders PLLC, dba Akina Pharmacy

    FDA warns Akina Pharmacy over unsafe production of compounded drugs and sterility risks.

    High risk
  29. QuVa Pharma, Inc.

    FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.

    High risk
  30. Curexa – East, LLC dba Curexa

    Curexa - East made compounded drugs under insanitary conditions, with contamination and inadequate cleaning, FDA says.

    High risk
  31. Southern Tier Home Infusion, Inc. dba Pharmacy Innovations

    FDA warned compounding pharmacy Pharmacy Innovations that its sterile drugs were made under insanitary conditions and without valid patient prescriptions.

    High risk
  32. US Specialty Formulations, LLC

    US Specialty Formulations, a drug compounder registered as an outsourcing facility, made sterile compounded drugs under insanitary conditions.

    High risk
  33. Pharmacy Plus, Inc., dba Vital Care Compounder

    FDA warned Pharmacy Plus (Vital Care Compounder) that its sterile compounded drugs were made under insanitary conditions, risking contamination.

    High risk
  34. Carolina Infusion

    FDA warns Carolina Infusion over compounded drugs made without valid prescriptions and under insanitary conditions, including sterile products.

    High risk
  35. ImprimisRx NJ

    FDA found insanitary sterile compounding and subpotent timolol-latanoprost eye drops at ImprimisRx NJ.

    High risk
  36. New England Life Care, Inc. dba Advanced Compounding Solutions

    FDA cites Advanced Compounding Solutions for insanitary sterile-drug production and CGMP failures after a 2022 inspection.

    High risk
  37. Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy

    FDA warns Drug Depot dba APS Pharmacy over compounded drugs made with ineligible bulk substances.

    Medium
  38. North American Custom Laboratories, LLC dba FarmaKeio Superior Custom Compounding

    FarmaKeio, a Texas compounding pharmacy, made sterile drugs under insanitary conditions that put patients at risk.

    High risk
  39. Optum Infusion Services 308 LLC

    FDA warned Optum Infusion Services 308 LLC about insanitary conditions in sterile drug compounding after inspection found vermin and microbial contamination.

    High risk
  40. Nephron Pharmaceuticals Corporation dba Nephron Sterile Compounding Center, LLC

    FDA warned Nephron Sterile Compounding Center about insanitary sterile drug production and sterility assurance failures found in a 2022 inspection.

    High risk
  41. Vita Pharmacy, LLC dba Talon Pharmacy of Boerne

    FDA warned Talon Pharmacy of Boerne that it made sterile compounded drugs under insanitary conditions that could contaminate them.

    High risk
  42. Hybrid Pharma, LLC

    FDA warned outsourcing facility Hybrid Pharma of Deerfield Beach, Florida, that sterile compounding violations made its drugs adulterated and unapproved.

    High risk
  43. New Vitalis, LLC dba New Vitalis Pharmacy

    New Vitalis Pharmacy made sterile compounded drugs under insanitary conditions that risked contamination.

    High risk
  44. Age Management Institute Santa Barbara

    FDA cited Age Management Institute Santa Barbara for insanitary sterile compounding of IV drugs, including dirty equipment and expired ingredients.

    High risk
  45. Med Shop Total Care, Inc.

    FDA warns Med Shop Total Care about insanitary conditions in sterile drug compounding.

    High risk
  46. Innoveix Pharmaceuticals Inc

    FDA cited Innoveix Pharmaceuticals for insanitary conditions in producing sterile compounded drugs, including improper sterilization and aseptic practices.

    High risk
  47. Apothecary Health Solutions/Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop

    FDA cited Carie Boyd's Prescription Shop for compounded drugs that failed outsourcing-facility labeling and reporting rules.

    Medium
  48. Advanced Nutriceuticals, LLC dba The Guyer Institute of Molecular Medicine

    Advanced Nutriceuticals compounded sterile drugs without required prescriptions and under insanitary conditions, FDA says.

    High risk
  49. Matthew 7:25 Inc dba Thrive Pharmacy

    FDA says Thrive Pharmacy compounded drugs without valid prescriptions and released subpotent buprenorphine troches, making them adulterated and misbranded.

    High risk
  50. Infusion Options, Inc.

    FDA found Infusion Options produced sterile compounded drugs under insanitary conditions and failed 503B labeling and reporting rules.

    High risk